CHICAGO — There are usually two standard treatment paths for patients with high-risk prostate cancer that has not spread. The prostate may be surgically removed or a combination of radiation therapy and hormone therapy may be used. Now, following the results of a new phase 3 clinical trial, some oncologists believe a third option may soon be considered. It is a surgery that uses hormone therapy before and after the surgery.
The study, known as the PROTEUS trial, found that a combination of two types of hormone therapy, one before surgery and one after surgery, was better than one hormone therapy alone, in high-risk, early-stage prostate cases.
However, how prostate cancer experts interpret the results varies. Many told STAT they believe this could lead to a new standard of care. Emmanual Antonarakis, a genitourinary oncologist at the University of Minnesota, called this a “watershed moment” for prostate cancer in an editorial in the New England Journal of Medicine.
STAT+ exclusive story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Subscribe to STAT+ for this article and daily biotech coverage and analysis.
Already have an account? Log in
Individual plan Group plan See all plans
To read the rest of this story, subscribe to STAT+.
Subscribe
Source link
